Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0
Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0
Not yet recruiting · NCT07682415 · Registry updated 2026-07-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0 | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 2 | 2026-07-02 | NCT07682415 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BeOne Medicines | 76 |
| Yi Shuhua | 1 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Blood Disease Hospital of Chinese Academy of Medical Sciences (Institute of Hematology, CAMS) | Tianjin | China | 1 |
| Henan Cancer Hospital | Zhengzhou | China | 98 |
| Jiangsu Province Hospital | Nanjing | China | 37 |
| Qilu Hospital of Shandong University | Jinan | China | 68 |
| Shenzhen Second People's Hospital | Shenzhen | China | 17 |
| The First Affiliated Hospital of Nanchang University | Nanchang | China | 77 |
| The Second Xiangya Hospital of Central South University | Changsha | China | 39 |